Targeting specific receptors to improve lung function in cystic fibrosis
Targeting fibroblast growth factor receptors in cystic fibrosis-associated airway inflammation and mucociliary dysfunction
This study is looking at how a new treatment that targets certain receptors in the lungs might help reduce inflammation and improve mucus clearance for people with cystic fibrosis, especially as they get older and deal with ongoing lung problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11009057 on NIH RePORTER |
What this research studies
This research investigates how targeting fibroblast growth factor receptors can help reduce airway inflammation and improve mucus clearance in patients with cystic fibrosis (CF). The study employs a combination of cell culture techniques and animal models to explore the effects of inhibiting these receptors on lung function. By focusing on primary human bronchial epithelial cells from different CF genotypes, the research aims to identify new therapeutic strategies that could benefit the aging CF population facing chronic lung issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those experiencing chronic airway inflammation and mucociliary dysfunction.
Not a fit: Patients without cystic fibrosis or those who do not exhibit airway inflammation or mucociliary dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for airway inflammation and mucus clearance in cystic fibrosis patients.
How similar studies have performed: Previous research has shown promise in targeting inflammatory pathways in cystic fibrosis, but this specific approach to FGFR inhibition is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Krick, Stefanie — University of Alabama at Birmingham
- Study coordinator: Krick, Stefanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.